In AQP4-positive NMOSD, relapse within 4 weeks of meningococcal vaccination was uncommon (3.3% overall). Findings support vaccination as a generally acceptable prerequisite before C5 inhibitor therapy, with causality still unclear.
Phase 3 trial data show daratumumab reduced relapse risk by 74% in NMOSD. Separately, the FDA accepted an NDA for iberdomide plus daratumumab/dexamethasone in relapsed/refractory multiple myeloma, with a PDUFA date of August 17, 2026.
Over 10 companies are developing 12+ pipeline therapies for Neuromyelitis Optica Spectrum Disorder, including Roche's satralizumab Phase III pediatric trial and multiple anti-CD20 monoclonal antibody candidates.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07775066 |
Pattern of AFP in Chhidren Admitted at Sohag University Hospital |
NOT_YET_RECRUITING | |
| NCT03887273 |
Study to Investigate the Safety of the Transplantation of Human Glial Restricted Progenitor Cells Into Subjects With Transverse Myelitis |
RECRUITING | PHASE1/PHASE2 |
